Atvivo LLC

Atvivo LLC was paid $22.04M by Medicaid between Dec 2020 and Dec 2023, across 7 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 78% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in New Jersey

Rank by total paid#17 of 122

Median peer was paid$1.29M

This provider vs. median17×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2020	23	$2K
2021	193,578	$7.77M
2022	335,910	$13.78M
2023	8,030	$489K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	78%	296,427	114,130	$17.16M
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	19%	232,432	101,876	$4.29M
87637	Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV	1.6%	3,896	3,831	$350K
0241U	Neonatal screening for hereditary disorders, genomic sequence analysis panel	<1%	808	792	$195K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	<1%	2,204	993	$44K
G2024	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) from an individual in a snf or by a laboratory on behalf of a hha, any specimen source	<1%	1,758	438	$6K
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	<1%	16	16	$23.46

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialKRAUS, MOSHE (COO)